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Activation of cGMP/Protein Kinase G Pathway in Postconditioned
Myocardium Depends on Reduced Oxidative Stress and Preserved
Endothelial Nitric Oxide Synthase Coupling
Javier Inserte, PhD; Victor Hernando, PhD; Ursula Vilardosa, MSc; Elena Abad, PhD; Marcos Poncelas-Nozal, MSc;
David Garcia-Dorado, MD, PhD, FAHA
Background-—The cGMP/protein kinase G (PKG) pathway is involved in the cardioprotective effects of postconditioning (PoCo).
Although PKG signaling in PoCo has been proposed to depend on the activation of the phosphatidylinositol 3-kinase (PI3K)/Akt
cascade, recent data bring into question a causal role of reperfusion injury signaling kinase (RISK) in PoCo protection. We
hypothesized that PoCo increases PKG activity by reducing oxidative stress–induced endothelial nitric oxide synthase (NOS)
uncoupling at the onset of reperfusion.
Methods and Results-—Isolated rat hearts were submitted to 40 minutes of ischemia and reperfusion with and without a PoCo
protocol. PoCo reduced infarct size by 48% and cGMP depletion. Blockade of cGMP synthesis (1H-[1,2,4]oxadiazolo[4,3-a]
quinoxalin-1-one) and inhibition of PKG (KT5823) or NOS (L-NAME) abolished protection, but inhibition of PI3K/Akt cascade
(LY294002) did not (n=5 to 7 per group). Phosphorylation of the RISK pathway was higher in PoCo hearts. However, this difference
is due to increased cell death in control hearts because in hearts reperfused with the contractile inhibitor blebbistatin, a drug
effective in preventing cell death at the onset of reperfusion, RISK phosphorylation increased during reperfusion without
differences between control and PoCo groups. In these hearts, PoCo reduced the production of superoxide (O2
) and protein
nitrotyrosylation and increased nitrate/nitrite levels in parallel with a significant decrease in the oxidation of tetrahydrobiopterin
(BH4) and in the monomeric form of endothelial NOS.
Conclusions-—These results demonstrate that PoCo activates the cGMP/PKG pathway via a mechanism independent of the PI3K/
Akt cascade and dependent on the reduction of O2
 production at the onset of reperfusion, resulting in attenuated oxidation of
BH4 and reduced NOS uncoupling. ( J Am Heart Assoc. 2012;2:e005975 doi: 10.1161/JAHA.112.005975)
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I schemic postconditioning (PoCo), a cardioprotective strat-egy consisting of brief episodes of intermittent coronary
reocclusions applied at the onset of reperfusion, represents a
feasible approach to limit infarct size in the clinical setting. An
increasing number of studies suggest that PoCo enhances
myocardial salvage and improves clinical outcomes in patients
with acute myocardial infarction who are receiving primary
percutaneous coronary intervention,1,2 but its exact mecha-
nisms have not been completely elucidated.3
Experimental evidence demonstrates that delayed nor-
malization of intracellular pH during initial reperfusion plays a
determinant role in the effectiveness of a PoCo protocol.4,5
In addition, the use of nitric oxide (NO) synthase (NOS),
guanylyl cyclase (GC), or protein kinase G (PKG) inhibitors
abolished the infarct-sparing effect of PoCo in different
studies,6–8 confirming the involvement of the NO-dependent
activation of the cGMP/PKG pathway in the cardioprotection
induced by PoCo. Among other mechanisms, it was recently
proposed that PKG activation contributes to PoCo protection
by delaying normalization of pHi during reperfusion, probably
via PKG-dependent inhibition of Na+/H+-exchanger.7 Acti-
vation of the cGMP/PKG pathway by PoCo has been
largely proposed to be dependent on the activation of the
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phosphatidylinositol 3-kinase (PI3K)/Akt cascade.3 However,
a recent study in the in situ pig model suggests that increased
reperfusion injury signaling kinase (RISK) phosphorylation is
not associated with a reduction in infarct size, questioning a
causal role of RISK in the protection induced by PoCo.9
On the other hand, it is well accepted that reactive oxygen
species (ROS), including superoxide (O2
), are acutely formed
and released during the first minutes of reperfusion.10,11
Formation of O2
 has been proposed to reduce the bioavail-
ability of NO by increasing the production of peroxynitrite
(ONOO) and the oxidation of tetrahydrobiopterin (BH4), a
cofactor needed for NOS coupling that has been shown to be
largely depleted during ischemia–reperfusion.12 PoCo, by pre-
venting an abrupt reperfusion, may reduce the burst of ROS and
increase the NO-mediated activation of the cGMP/PKG path-
way. However, no studies have been performed to investigate
the effect of PoCo on NOS coupling. The aims of our study were
to (1) demonstrate that activation of PKG/cGMP pathway is
independent of PI3K/Akt signaling and that the increased
phosphorylation of RISK observed in PoCo is a consequence but
not a cause of the reduction in cell death in a rodent model and
(2) determine whether PoCo activates the cGMP/PKG pathway
by increasing the coupling of eNOS as consequence of reduced
oxidative stress and preserved levels of BH4.
Methods
The experimental procedures conformed to the “Guide for the
Care and Use of Laboratory Animals” published by the US
National Institutes of Health (NIH Publication No. 85-23,
revised 1996) and were approved by the Research Commis-
sion on Ethics of the Hospital Vall d’Hebron.
Isolated Perfused Rat Heart Preparation
Male Sprague–Dawley rats (300 to 350 g) were anesthetized
with sodium pentobarbital (100 mg/kg). Hearts were
removed, mounted onto a Langendorff apparatus, and
perfused with a modified Krebs–Henseleit bicarbonate buffer
(KHB, in mmol/L: NaCl 140, NaHCO3 24, KCl 2.7, KH2PO4
0.4, MgSO4 1, CaCl2 1.8, and glucose 11) equilibrated with
95% O2 and 5% CO2 as described previously.
5 Flow rate was
initially adjusted to produce a perfusion pressure of
60 mm Hg and was held constant thereafter. Left ventricular
(LV) pressure was monitored through the use of a water-filled
latex balloon inserted into the left ventricle and inflated to
obtain an end-diastolic pressure (LVEDP) between 6 and
8 mm Hg. LV developed pressure was calculated as the
difference between LV systolic pressure and LVEDP. Perfusion
pressure was continuously recorded using a pressure trans-
ducer connected to the perfusion line.
Experimental Protocol
The different experimental protocols are illustrated in
Figure 1. In control group, hearts were subjected to global
ischemia for 40 minutes followed by reperfusion of a
different duration. PoCo was achieved with a previously
established protocol consisting of 6 cycles of 10-second
reperfusion–10-second occlusion (PoCo group).5 In addi-
tional groups of hearts, the inhibitor of soluble guanylate
cyclase (3 lmol/L 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-
1-one [ODQ], Sigma-Aldrich), PKG (1 lmol/L KT-5823,
Sigma-Aldrich), NOS (100 lmol/L L-NAME Sigma-Aldrich),
or PI3K (15 lmol/L LY294002, Sigma-Aldrich) was added
during the first 10 minutes of reperfusion.
In those experiments aimed to analyze a variable different
than cell death, the selective contractile inhibitor blebbistatin
(10 lmol/L, Merck)13 was added during reperfusion or after
60 minutes in hearts perfused with oxygenated buffer (Nx).
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Figure 1. Experimental protocol. In a first set of experiments,
isolated rat hearts were subjected to 40 minutes of ischemia and
60 minutes of reperfusion with and without postconditioning (PoCo)
consisting of 6 cycles of 10 seconds of ischemia and 10 seconds of
reperfusion. In a second set of experiments, control and PoCo
hearts received the contractile inhibitor blebbistatin at the onset of
reperfusion. Samples for Western blots and measurement of NOx
released to the coronary effluent were obtained at different times
(A) and other parameters were measured after 5 minutes of
reperfusion (B). In both set of experiments, the different drugs
were given during the first 10 minutes of reperfusion (drug
treatment: KT-5823, ODQ, L-NAME, LY-294002, SIN-1, BH4). LDH
indicates lactate dehydrogenase; NOx, total nitrate/nitrite; eNOS,
endothelial nitric oxide synthase; WB, Western blots; ONOO,
peroxynitrite; ODQ, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; BH4,
tetrahydrobiopterin; O2
, superoxide; SIN-1, 3-morpholinosydnonimine.
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Blebbistatin prevents sarcolemmal rupture and cell death by
reducing the mechanical stress caused by the excessive
contractile activation occurring at the onset of reperfusion. It
was used to discard the possibility that any variation on the
measured parameters was a mere consequence of differences
in cell death associated with sarcolemmal disruption. This
strategy has been previously used with the less-specific
contractile inhibitor butanedione monoxime.14
Quantification of Cell Death
Lactate dehydrogenase (LDH) activity was spectrophotometri-
cally measured in the coronary effluent throughout the reper-
fusion period. After 60 minutes of reperfusion, heart sliceswere
incubated in 1% TTC to outline the area of necrosis as previously
described (n=7 per group except controls with L-NAME, ODQ,
and KT-5823, n=5).15 Previous studies demonstrated that in the
Langendorff rat model, reperfusion for 60 minutes is sufficient
for acute assessment of infarct size.16,17
Protein Phosphorylation
Protein phosphorylation was measured in heart samples
homogenized in buffer containing Tris-HCl 50 mmol/L, NaCl
150 mmol/L, EDTA 10 mmol/L, DTT 1 mmol/L, NaF 10
mmol/L, Na3VO4 2 mmol/L, 1% Triton X-100, and 1%
Protease Inhibitor Cocktail (Sigma), pH 7.3, and centrifugated
at 15 000g during 15 minutes. Samples from supernatants
were separated via electrophoresis on 7.5% to 12% SDS gels
with a Tris-glycine-SDS running buffer (Sigma), transferred
onto nitrocellulose membrane (Hybond ECL, Amersham),
blocked with 5% PhosphoBlocker Blocking Reagent (Cell
Biolabs, Inc), and immunoblotted with antibodies against
eNOS Ser1177 (BD Transduction Laboratories), Akt Ser473,
GSK-3b Ser9, and ERK1/2 Thr202/Tyr204 (Cell Signaling
Technology). Membranes were reprobed with antibodies
against the total form of the respective protein. Bands were
detected via chemiluminiscence (SuperSignal West Dura
Extended Duration Substrate, Pierce) and quantified using a
charge-coupled device system (Image Reader LAS-3000,
Fujifilm) and image analysis software (Image Gauge, Fujifilm).
Hearts normoxically perfused (Nx) for 60 minutes were used
as reference of the stress activation associated with the
Langendorff preparation.18 Equal protein load was confirmed
with Ponceau staining. Signals from the phosphorylated form
of a given kinase were normalized to its total content and final
values were obtained from 4 different samples.
Quantification of Superoxide Production
Oxidation of the cell permeant fluorescent dye dihydroethi-
dium (DHE) to ethidium and hydroxyethidium was used to
measure O2
.12 Hearts were perfused with 8 lmol/L DHE
and blebbistatin during the first 5 minutes of reperfusion and
homogenated in buffer containing Tris-HCl 50 mmol/L, NaCl
150 mmol/L, EDTA 10 mmol/L, 1% Triton X-100, and 1%
Protease Inhibitor Cocktail (Sigma), pH 7.3 (n=6 per group
except for PoCo groups reperfused with ODQ and L-NAME
[n=5 per group]). Two hundred microliters of each sample was
read in a Spectra MAX GEMINI plate reader (510 nm
excitation and 590 nm emission) to measure the formation
of the O2
-derived ethidium and hydroxyethidium. Back-
ground fluorescence was substracted and results were
normalized for protein content. To discard nonspecific effects
of blebbistatin, DHE staining was measured in control and
PoCo hearts reperfused for 5 minutes in the absence of
blebbistatin (n=6 per group).
To determine the major source of ROS impacted by PoCo
in our experimental model, additional groups of hearts
subjected to the ischemia/reperfusion protocol with or
without PoCo were perfused throughout the perfusion proto-
col with the xanthine oxidase inhibitor allopurinol (1 mmol/L,
Sigma), the NADPH oxidase inhibitor apocinin (100 lmol/L,
Sigma), or BH4 (100 lmol/L, Merck) (n=5 per group).
Measurement of Nitrotyrosine Formation
The modification of protein tyrosine residues to 3-nitrotyro-
sine, a footprint of in vivo ONOO formation, was measured
by SDS-PAGE Western blotting.19 Myocardial samples
obtained after 5 minutes of reperfusion (n=3 per group) were
prepared, and proteins were separated via electrophoresis on
12% SDS gels and transferred onto nitrocellulose membrane
as described for protein phosphorylation. The primary
3-nitrotyrosine antibody (Millipore) was used at 1:500.
Samples from control and PoCo hearts perfused with the
ONOO donor 3-morpholinosydnonimine (SIN-1 100 lmol/L,
Tocris) added to the buffer during reperfusion were used as
positive control.
Measurement of Myocardial Biopterin
BH4 and BH2 contents were determined in cardiac homogen-
ates obtained after 5 minutes of reperfusion (n=6). Hearts
were rapidly excised and stored at 80°C. Samples were
homogenized in buffer containing Tris-HCl 50 mmol/L, EDTA
1 mmol/L, DTT 1 mmol/L, and 0.1 mg/ml ascorbic acid, pH
7.4 and centrifugated at 100 000g for 30 minutes. Concen-
tration of biopterins were determined by high-performance
liquid chromatography analysis using a differential oxidation
method as previously described20 and corrected for protein
concentration. Control hearts supplemented with BH4
100 lmol/L during reperfusion were used as positive control
(n=5).
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Dimeric and monomeric forms of eNOS were analyzed in
hearts reperfused for 5 minutes and homogenized in buffer
containing Tris-HCl 50 mmol/L, NaCl 150 mmol/L, EDTA
10 mmol/L, DTT 1 mmol/L, NaF 10 mmol/L, Na3VO4 2
mmol/L, 1% Triton X-100, and 1% Protease Inhibitor Cocktail
(Sigma), pH 7.3 (n=3 per group). Proteins were separated via
low-temperature electrophoresis on a 6% SDS gel with
Tris-glycine-SDS running buffer (Sigma), transferred in the
presence of 0.01% SDS, and immunoblotted with antibody
against total eNOS (BD Transduction Laboratories).21
Nitrate/Nitrite Determination
Total nitrate/nitrite (NOx) levels were measured in myocardial
and coronary effluent samples from control and PoCo groups
obtained under normoxic conditions and at 3, 5, 10, and
30 minutes of reperfusion (n=5 for each time point) by using an
NOx fluorometric assay kit according to the manufacturer’s
directions (Cayman Chemical Co).22 Myocardial NOx was also
measured in control and PoCo hearts reperfused for 5 minutes
with LY294002 (n=5), L-NAME (n=5), BH4 (n=5), and SIN-1 (n=4).
To discard nonspecific effects of blebbistatin, myocardial NOx
levels were measured in control and PoCo hearts reperfused for
5 minutes in the absence of blebbistatin (n=5 per group).
Measurement of Myocardial cGMP Content
Myocardial cGMP was measured in extracts23 from heart
samples obtained from the different groups of treatment at
5 minutes of reperfusion (n=6 per group except groups
reperfused with ODQ and L-NAME [n=5 per group]) with a
commercial cGMP EIA kit (Cayman Chemical Co) following
manufacturer’s instructions.
Statistical Analysis
Data analysis was performed using SPSS for Windows. Means
between groups were compared by 1-way ANOVA or unpaired t
test. Least significant difference test was applied as post-hoc
test when significant differences were observed. A 2-way ANOVA
was used to examine the effect of PoCo and the different drugs
added at reperfusion on cell death and myocardial cGMP and
NOx content, DHE fluorescence, and the effect of PoCo and the
time of reperfusion on protein phosphorylation and myocardial
NOx. Significant differences between PoCo and its corresponding
control group were determined by simple main effect analysis.
Repeated-measures ANOVA was used to compare temporal
differences in LDH and NOx released into the effluent. P<0.05
was considered to be statistically significant. The linear regres-
sion of protein phosphorylation on infarct size, corrected for
group effect, was estimated using the general linear model with
groups introduced as a fixed factor. In all cases, the assumption
of normality was examined in SPSS before the statistical analysis
using the Shapiro–Wilk test. When P>0.05, distribution of data
was considered normal. All results are expressed as meanSEM.
Results
NO-Dependent Activation of cGMP/PKG Pathway,
but Not PI3K/Akt Cascade, Mediates
Postconditioning Protection
No differences among groups were observed in LV function
during the equilibration and the ischemic period. At the end of
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Figure 2. Quantification of reperfusion-induced cell death and
cGMP content in control and postconditioned (PoCo) hearts in the
presence of the different inhibitors. A, Total LDH released during
reperfusion and (B) infarct size measured by TTC and expressed as
percentage of ventricular mass. C, Myocardial cGMP content
measured in hearts perfused under normoxic conditions (Nx) and
in hearts subjected to 40 minutes of ischemia and 5 minutes of
reperfusion in the presence of blebbistatin. *P<0.05 vs control
group. Data are meanSEM. LDH indicates lactate dehydrogenase.
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were, respectively, 6.50.7 and 93.85.4 mm Hg, perfusion
pressure was 63.13.7 mm Hg, and coronary flow was
12.31.5 mL/min. On the contrary, during the reperfusion
period, hearts subjected to PoCo (PoCo group) showed
delayed (3.80.2 versus 6.50.3 minutes in control group,
P<0.001) and attenuated hypercontracture (138.27.9 ver-
sus 99.35.1 mm Hg, P<0.001) and markedly reduced LDH
(P<0.001, Figure 2A) and infarct size (P<0.001, Figure 2B)
and increased myocardial cGMP levels (P<0.001, Figure 2C).
Treatment of hearts with either the soluble GC (sGC) inhibitor
ODQ, the PKG blocker KT5823, or the NOS inhibitor L-NAME
abolished the effects of PoCo on hypercontracture, cell death,
and cGMP content (Figure 2). In contrast, no effect of the
PI3K inhibitor LY294002 on cell death and cGMP (Figure 2)
was observed. Effective blockade of Akt phosphorylation by
LY294002 administered during reperfusion was confirmed in
heart samples obtained after 10 and 30 minutes of reperfu-
sion, demonstrating that the lack of effect on cell death
obtained with PI3K/Akt blockade was not the consequence of
inadequate drug administration (Figure 3).
Phosphorylation of RISK Is a Consequence but
Not a Cause of Postconditioning Protection
The addition of the contractile inhibitor blebbistatin to the
perfusion buffer at the onset of reperfusion prevents the
development of hypercontracture (Figure 4A) and cell death
associated with mechanical stress (Figure 4B). Blebbistatin
was used to discard the possibility that any variation on
protein phosphorylation was a consequence of differences in
cell death. The use of blebbistatin abolished the differences
between the control and PoCo groups in the extent of cell
death (Figure 5).
PoCo hearts reperfused for 30 minutes showed a marked
increase in the phosphorylation of Akt (P<0.001) and in the
RISK downstream effector GSK-3b (P<0.001) with respect to
control hearts. However, when blebbistatin was added during
reperfusion, and cell death in both control and PoCo hearts
was markedly reduced, differences between groups in protein
phosphorylation measured at 30 minutes of reperfusion were
abolished (Figure 5A and 5B). Blebbistatin had no effect on
protein phosphorylation in normoxically perfused hearts,
demonstrating that the increased phosphorylation observed
during reperfusion is a consequence of reduced cell death and
not of a blebbistatin-dependent activation of RISK. A scatter
plot that included control and PoCo groups reperfused with
and without blebbistatin disclosed a close correlation between
infarct size and phosphorylation. For Akt, the general linear
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Figure 3. Effect of the phosphatidylinositol 3-kinase (PI3K) inhib-
itor LY294002 on Akt phosphorylation measured after 10 and
30 minutes of reperfusion. *P<0.05 vs respective postconditioned
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Figure 4. Effect of blebbistatin on left ventricular pressure (LVP)
and cell death. A, Representative LVP corresponding to control
(upper panel) and hearts receiving blebbistatin during 5 minutes of
reperfusion (lower panel). B, Time course of LDH release during the
first 30 minutes of reperfusion. *P<0.05. Data are meanSEM. LDH
indicates lactate dehydrogenase.
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model analysis shows a significantly negative regression of
protein phosphorylation on infarct size (P<0.039), the effects
of groups, corrected for covariation with infarct size, being
nonsignificant (P<0.282). A similar pattern was observed for
GSK-3b but, in this instance, the test for negative regression
did not reach significance (P<0.085). It is worth noting that the
regression slope computed from the pooled data by ignoring
groups is significantly negative in both instances (P<0.0022 for
Akt, P<0.0021 for GSK-3b) (Figure 5C).
The time course of protein phosphorylation in control
hearts treated with blebbistatin showed a sustained
increase in phosphorylation of all measured proteins during
reperfusion with a plateau at 10 minutes for ERK1/2 and
GSK-3b and at 30 minutes for Akt and eNOS (Figure 6).
PoCo produced a delay in protein phosphorylation of Akt/
GSK-3b during the first minutes of reperfusion, although the
initial differences were progressively reduced, and after
30 minutes of reperfusion, phosphorylation of all measured
proteins was similar between control and PoCo groups
(Figure 6).
An Alternative Mechanism: Postconditioning
Increases NOS Coupling by Preserving BH4
Myocardial BH4 concentration measured in control hearts was
markedly depleted after 5 minutes of reperfusion (1.020.22
versus 3.080.37 pmol/mg protein in normoxically perfused
hearts, P<0.001). These values are similar to those reported
previously in the isolated rat heart.12 PoCo increased the ratio
of reduced BH4 to oxidized biopterins, although without
reaching preischemic values of BH4 (P=0.038 compared with
control hearts) (Figure 7A).
To investigate the effect of BH4 preservation on the
stability of eNOS dimer, the ratio between dimeric and
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Figure 5. Correlation between phosphorylation of phosphatidylinositol 3-kinase (PI3K)/Akt pathway and cell death. A, Western blot showing the
phosphorylation of Akt and GSK-3b in control and postconditioned (PoCo) hearts after 30 minutes of reperfusion with and without blebbistatin.
B, Quantification of phosphorylation and LDH released during 30 minutes of reperfusion in the different groups. C, Scatter plot and regression
analysis showing the correlation between the magnitude of Akt and GSK-3b phosphorylation and cell death (LDH). *P<0.05 vs respective control
group. Data are meanSEM. LDH indicates lactate dehydrogenase.
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monomeric forms of eNOS was determined through separa-
tion of heart homogenates using low-temperature electropho-
resis. The results obtained demonstrated a close correlation
between the reduced:oxidized biopterins ratio and the eNOS
dimer:monomer ratio. The dimeric form of eNOS was
markedly reduced in homogenates from control hearts
measured after 5 minutes of reperfusion, whereas PoCo
significantly increased the dimeric and reduced the mono-
meric eNOS (P<0.001). Perfusion with external BH4 pro-
duced an additional increase in the dimer:monomer ratio
(Figure 7B).
The increased eNOS coupling in PoCo hearts was
confirmed by measuring the time course of NOx generated
in myocardium and released into the coronary effluent during
the first 30 minutes of reperfusion. NOx levels fell in
myocardium at the onset of reperfusion in control hearts
and showed no significant recovery in myocardium
(Figure 8A) and a gradual decrease in the coronary effluent
(Figure 8B). PoCo attenuated NOx drop at the onset of
reperfusion and levels remained higher than in control hearts
throughout the reperfusion period (P=0.005 in myocardial
samples and P=0.003 in samples from coronary effluent). As
shown in Figure 8C, perfusion with L-NAME but not with
LY294002 attenuated the production of NOx observed in
PoCo myocardial samples obtained after 5 minutes of reper-
fusion. BH4 increased NOx level in the control group (P=0.032
compared with untreated control group) and had no additive
effect when combined with PoCo. Increased NOx production
in PoCo hearts was confirmed in an additional group of hearts
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Figure 6. Time course of Akt, ERK1/2, GSK-3b, and eNOS phosphorylation in samples from hearts corresponding to control (C) and
postconditioned (P) groups obtained before reperfusion and after 3, 5, 10, and 30 minutes of reperfusion in presence of blebbistatin (R). Data are
expressed as fold increase compared with ischemia (I). Nx corresponds to hearts normoxically perfused for 60 minutes. *P<0.05 vs respective
control group. eNOS indicates endothelial nitric oxide synthase.
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control hearts versus 5.580.206 nmol/mg protein in PoCo
hearts, P=0.009).
Postconditioning Preserves BH4 by Reducing O2

Production and Oxidative Stress
Superoxide production was assessed by DHE oxidation
fluorescence. Fluorescence measured after 5 minutes of
reperfusion with DHE in the presence of blebbistatin
increased in control hearts compared with normoxically
perfused hearts (P<0.001, Figure 9A) and was prevented by
PoCo. Inhibition of the cGMP/PKG pathway with ODQ or
KT-5823 did not modify fluorescence at the onset of
reperfusion, confirming that O2
 reduction by PoCo is
upstream PKG activation. Prevention of O2
 production by
PoCo was confirmed in an additional group of hearts perfused
without blebbistatin (2.580.09 AU in control hearts versus
1.830.11 AU in PoCo hearts, P=0.001).
The addition of allopurinol to the perfusion buffer reduced
DHE fluorescence in control hearts (P<0.001 versus
untreated control group), whereas perfusion with apocynin
or L-NAME had no effect. The perfusion of hearts with
external BH4 produced a nonstatistically significant trend
toward attenuation (P=0.116 versus control group). None of
these treatments had an additive effect when combined
with PoCo. These results suggest that the major pool of
O2
 reduced by PoCo is generated by xanthine oxidase
(Figure 9B).
To confirm that PoCo reduces O2
 and attenuates the
oxidative stress at the onset of reperfusion, protein nitroty-
rosilation was measured by Western blotting as an index
eNOS
Nx              C             PoCo         BH4
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Figure 7. Effect of postconditioning on BH4 and eNOS coupling
after 40 minutes of ischemia and 5 minutes of reperfusion.
A, Quantification of the ratio between reduced and oxidated BH4.
B, Representative Western blot and quantification of the SDS-
resistant eNOS dimer. Positive control was obtained by adding
external BH4 to the buffer during reperfusion. *P<0.05 vs Nx group.
$P<0.05 vs control group. Data are meanSEM. Nx indicates
normoxically perfused group; C, control group; PoCo, postcondi-
tioned group; eNOS, endothelial nitric oxide synthase; BH4, tetrahy-
drobiopterin.
Time (min)














































































Figure 8. Effect of postconditioning on nitrate/nitrite concentra-
tion (NOx). A, Myocardial NOx content and (B) NOx released to the
coronary efluent in normoxically perfused hearts (Nx) and at 3, 5, 10,
and 30 minutes of reperfusion after 40 minutes of ischemia in
control and preconditioned (PoCo) hearts. C, Myocardial NOx content
measured in heart samples obtained after 40 minutes of ischemia
and 5 minutes of reperfusion. *P<0.05 vs respective control group.
$P<0.05 vs untreated control group.
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of in vivo ONOO formation. In samples corresponding to
control hearts reperfused for 5 minutes immunoblotted
against 3-nitrotyrosine, a marked band of 30 kDa appeared
that was significantly attenuated in the PoCo group (P<0.001,
Figure 10). The specificity of this band was confirmed by
perfusing the hearts with the ONOO donor SIN-1. Perfusion
of PoCo hearts with SIN-1 increased the formation of
nitrotyrosine to values similar to those obtained in control
hearts.
Administration of BH4 during the first minutes of reperfu-
sion produced a nonstatistically significant trend toward
infarct size reduction (61.94.8% in control group versus
51.33.5% in postconditioned group, P=0.111) and resulted
in increased protein nitrosylation.
Discussion
The present study demonstrates that the increased NO-
dependent cGMP/PKG signaling induced by PoCo is due to
reduced formation of O2
 at the onset of reperfusion resulting
in attenuated oxidation of BH4, which reduces NOS uncou-
pling and increases NO availability. Our results further support
an important role of cGMP in PoCo protection but suggest
that the increased phosphorylation of RISK observed in PoCo
hearts is a consequence but not a cause of the reduction in
cell death. These results should assist in the development of
therapeutic strategies aimed to reduce reperfusion injury and
infarct size in patients.
Myocardial cGMP/PKG signaling is severely depressed in
cardiomyocytes and endothelial cells after prolonged ische-
mia.23,24 There is abundant evidence supporting that preser-
vation of this pathway with NO donors, natriuretic peptides, or
cGMP analogs attenuates cell death associated with reperfu-
sion.23,25,26 More recently, the blockade of cGMP/PKG
pathway by using NOS, sGC, or PKG inhibitors abolished the
infarct-sparing effects of PoCo, demonstrating that cGMP-
mediated signaling is involved in the mechanisms responsible
for PoCo-induced cardioprotection.6,7 Preservation of cGMP
by PoCo has been suggested to participate in different
molecular mechanisms through the activation of PKG. PKG
has been shown to inhibit the opening of mitochondrial
KATP,27 attenuate Ca2+ oscillations,26 and reduce the sensi-
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Figure 9. Measurement of O2 production using DHE after
40 minutes of ischemia and 5 minutes of reperfusion. A, Effect of
ischemic postconditioning and the cGMP/protein kinase G) pathway
on the production of O2
. B, Effect of inhibitors of ROS generation.
Hearts were perfused with the xanthine oxidase inhibitor allopurinol
(Allop.), NADPH oxidase inhibitor apocynin (Apoc.), or the reactive
oxygen species cofactor BH4. DHE fluorescence is expressed as
arbitrary units (a.u). *P<0.05 vs Nx group. $P<0.05 vs control group
without treatment. Data are meanSEM. Nx indicates normoxically





























Figure 10. Effect of ischemic postconditioning on the production
of ONOO after 40 minutes of ischemia and 5 minutes of reperfu-
sion. Representative Western blot showing a nitrotyrosylated 30-kDa
band, a marker of endogenous ONOO generation. Positive control
was obtained by perfusing the hearts with the ONOO donor
3-morpholinosydnonimine (SIN-1). *P<0.05 vs Nx group. Data are
meanSEM. Nx indicates normoxically perfused group; C, control
group; PoCo, postconditioned group; ONOO, peroxynitrite.
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proposed that PKG activation contributes to PoCo protection
by delaying normalization of pHi during reperfusion, probably
via inhibition of Na-H exchanger.7
PKG is commonly admitted to be a downstream effector of
the PI3K/Akt cascade.29 According to this pathway,
phosphorylation of the RISK component Akt results in
phosphorylation-dependent activation of eNOS and the con-
sequent NO-dependent activation of sGC. However, recent
studies in different models suggest that RISK phosphorylation
during reperfusion is not associated with a reduction in infarct
size.9,30,31 By comparing protein phosphorylation in myocar-
dial biopsy samples obtained from viable regions within the
area at risk after reperfusion with and without PoCo, it has
been demonstrated that RISK phosphorylation is not causally
involved in ischemic PoCo in pigs.9 Our data go beyond these
studies in that they provide a plausible explanation for the
discrepancies in the role of RISK. Studies showing an
association of RISK phosphorylation with less infarction used
animal models in which the small amount of viable tissue
makes technically impossible the approach taken by Skysch-
ally et al in pigs and, therefore, the samples collected from the
area at risk contains more viable cells in PoCo myocardium
resulting in an increased phosphorylation potential. This
technical limitation was also tested by Skyschally et al in
comparing protein phosphorylation from necrotic and viable
myocardium samples obtained after 10 minutes of reperfu-
sion, and they found no differences.9 Although authors
suggested that tissue udergoing infarction was not dead
yet, they did not measure phosphorylation after more
prolonged reperfusion. In our study, to rule out the possibility
that the effects of PoCo on protein phosphorylation were just
a reflection of its effect on cell death, hearts were reperfused
in the presence of the contractile inhibitor blebbistatin.
Contractile inhibition has been consistently demonstrated to
attenuate mechanical stress associated with hypercontrac-
ture and to prevent sarcolemmal rupture and cell death at the
onset of reperfusion.14,32,33 Using this approach, we demon-
strated a close correlation between the magnitude of protein
phosphorylation and the extent of cell death that is indepen-
dent of the perfusion protocol. In the absence of differences
in cell death, phosphorylation of Akt, ERK, and their proposed
downstream effectors eNOS and GSK-3b was similar in both
groups after 30 minutes of reperfusion or even lower in the
PoCo group during the first 10 minutes, a time interval of
critical importance in reperfusion injury.34 Moreover, blockade
of NOS, sGC, and PKG, but not PI3K, abolished the
cardioprotective effects of PoCo, confirming that activa-
tion of the cGMP/PKG pathway depends on activation of NOS
but cannot be explained by the activation of PI3K/Akt
cascade.
In the present study, we propose an alternative mechanism
to explain the NO-dependent activation of cGMP/PKG path-
way by PoCo. Numerous studies describe a burst of ROS
within the first minutes of reperfusion and support their
contribution to reperfusion injury.35 It has been suggested
using an in vivo rat model that PoCo may reduce ROS
generation immediately at reperfusion by limiting the delivery
of oxygen during the controlled reperfusion.36 Our results
confirm that PoCo attenuates the formation of O2
 at the
onset of reperfusion, suggest that this reduction mainly
involves O2
 produced by xanthine oxidase activity, and
demonstrate that the associated reduction of oxidative stress
mediates the eNOS-dependent activation of the cGMP/PKG
pathway. The lack of effect of sGC or PKG inhibition on O2

production supports that ROS reduction by PoCo is upstream
PKG activation. Attenuation of O2
 generation by PoCo may
have different effects. O2
 combines with NO at a very fast
rate to form ONOO, a potent oxidant implicated in a number
of pathophysiological processes.37 Peroxynitrite not only
reduces the availability of free NO but also, due to its high
reactivity and diffusibility,38 produces toxic effects through
the oxidation of lipids, sulfhydrils, DNA, and redox molecules
and the nitration of protein tyrosine residues.39 Prevention of
ONOO formation during reperfusion has been generally
associated with reduced reperfusion injury.40,41 In the present
study, by measuring protein nitrotyrosilation, a fingerprint of
the presence of ONOO in vivo, and using as positive control
samples from hearts perfused with the ONOO donor SIN-1,
we demonstrate that PoCo attenuates the formation of
ONOO. These results are consistent with a recent study
showing a reduction of nitro-oxidative stress by PoCo in an in
vivo rat model.42 In that study, the reduction in protein
nitrosylation by PoCo was interpreted as a consequence of
inhibited iNOS activity. However, no expression of iNOS after
5 minutes of reperfusion has been observed in our experi-
mental model.
ONOO may act directly on the eNOS heme group,
producing the inactivation of the enzyme.43 In addition, O2

and/or ONOO can oxidize BH4, a cofactor essential for
proper function of NOS,44 leading to NOS uncoupling and
preferential production of O2
 rather than NO.45,46 BH4 is
dramatically reduced during ischemia–reperfusion,12 and
administration of BH4 has been found to ameliorate NOS
activity and to reduce reperfusion injury.12,47 Our results
confirm the oxidation of BH4 at the onset of reperfusion and
demonstrate that PoCo attenuates BH4 depletion and
increases eNOS coupling as evaluated by the increase in
the dimeric form of eNOS and in the nitrite levels in the
coronary effluent. The BH4:oxidated biopterins ratio closely
correlated with the ratio of dimeric to monomeric forms of
eNOS. NOS uncoupling has been shown to increase O2

generation in postischemic hearts.12 In our study, BH4
supplementation was associated to a nonstatistically signif-
icant trend toward reduced O2
 production, suggesting that
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O2
 generated by uncoupled eNOS was not the main cause of
the reduction of oxidative stress by PoCo, and failed to reduce
infarct size. The failure of BH4 to protect against reperfu-
sion injury despite increasing eNOS coupling and NOx levels
can be explained according to the mechanism proposed in
Figure 8. Although PoCo preserves BH4 by reducing ROS
production, the administration of external BH4 during reper-
fusion increased the levels of BH4 without significantly
reducing myocardial ROS. In agreement with our data, it has
been recently shown that oral BH4 treatment augments the
levels of biopterins in patients with coronary artery disease
without affecting vascular function or O2
 production.48 In our
study, perfusion with BH4 increased the formation of perox-
ynitrite, an effect that could counterbalance the potential
cardioprotective actions of BH4.
Besides the activation of the cGMP/PKG pathway, other
signaling events have been proposed to be decisive in PoCo
protection that are compatible with the results obtained
in our study. PKG activation contributes together with
reduced lactate washout to delay pHi correction,7 which has
a beneficial effect on many mechanisms implicated in
reperfusion injury,49 including attenuation of the mechanical
stress associated to development of hypercontracture and
formation of mitochondrial permeability transition. It can be
hypothesized that by preventing these critical events during
early reperfusion, prolongation of acidosis allows the activa-
tion of the survivor activating factor enhancement (SAFE)
pathway to continue inhibiting mitochondrial permeability
transition after pHi normalization. In fact, the activation of
mitochondrial signal transducer and activator of transcription
3 (STAT-3) has been recently proposed to mediate post-
conditioning cardioprotection through better mitochondrial
function.50 Furthermore, besides activation of PKG, ROS
scavenging is a means of reducing a major stimulus for
mitochondrial permeability transition during reperfusion.51,52
A potential limitation of our study is the use of an isolated
rodent heart. The perfusion with a cristalloid buffer, which
requires higher oxygen tension and lacks of the intrinsic
erythrocyte antioxidant defenses, may exaggerate the pro-
duction of ROS. However, it has been proposed that in the
Langendorff model, O2 tension is inversely related to the burst
of radical production53 and that oxygen free radicals are
generated in even higher concentration at reperfusion after
regional ischemia in situ than after global ischemia in the
isolated perfused rabbit heart.54 However, there is agreement
that there are differences in the time course of ROS
generation between isolated heart and the in situ models.
Spin trap resonance shows a maximal free radical intensity
within the first minute of reperfusion before quickly dropping
to near baseline levels in the isolated heart model,55 whereas
in the in situ model, after the first burst of ROS, neutrophil
infiltration prolongs O2
 generation mainly through NADPH
oxidase activity.56 Because PoCo mediates its effects during
the first minutes of reperfusion, which are of critical
importance for reperfusion injury, our results may still be
valid in the in vivo model.
Our results suggest that PoCo attenuates O2
 produced by
xanthine oxidase activity. In earlier studies, xanthine oxidase
has been identified as an important source of ROS at
reperfusion in rodents.57 However, its contribution as a source
of O2
 generated during ischemia–reperfusion in the human
heart remains controversial. Although some studies suggest
that xanthine oxidase is not expressed in human myocar-
dium,58 other studies demonstrate its presence and the
reduction of markers of oxidative stress in patients treated
with allopurinol.59–61 Because the burst of ROS generated at
the onset of reperfusion has been described in humans and
protocols that limit the delivery of oxygen, such as PoCo,
reduce ROS generation independently of their source, we are
convinced that our results have translational relevance.
In conclusion, our data demonstrate that activation of the
PKG/cGMP pathway by PoCo in the isolated and perfused rat
heart is independent of PI3K/Akt activation and dependent on
reduced oxidative stress during reperfusion. Our study shows
that attenuation of O2
 and/or ONOO at the onset of
reperfusion by PoCo limits the oxidation of BH4 and reduces
eNOS uncoupling, increasing NO-dependent activation of
cGMP/PKG pathway (Figure 11). These results contribute to










Figure 11. Proposed mechanism for NO-dependent activation of
cGMP/protein kinase G (PKG) pathway by postconditioning (PoCo).
The present study provides data (in red) demonstrating that PoCo
attenuates the burst of O2
 generated at the onset of reperfusion,
reducing oxidative stress and eNOS uncoupling. NO indicates nitric
oxide; ONOO, peroxynitrite; O2
, superoxide; eNOS, endothelial
nitric oxide synthase; BH4, tetrahydrobiopterin; sGC, soluble guanylyl
cyclase.
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ischemic PoCo, a critical step necessary for its translation to
the clinical scenario, and should orientate the development of
pharmacological interventions able to reproduce the cardio-
protective effects of PoCo in patients subjected to reperfusion
after myocardial ischemia.
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